Elevance Health, Inc. vs Johnson & Johnson — Stock Comparison
Elevance Health, Inc. (ELV) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of Elevance Health, Inc. on Q·Score (7.1 vs 5.9 out of 10), led by Quality (9.3 vs 6.2) and Valuation (7.3 vs 5.9). Elevance Health, Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for JNJ (+9.5%) than for ELV (+3.5%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
68% of 22 covering analysts have a positive rating.
⚠ earnings contracting 17% year-over-year.
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ELV vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Elevance Health, Inc. (ELV) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ELV or JNJ?
Johnson & Johnson (JNJ) scores higher on Growth (5.1/10 vs 3.9/10). Elevance Health, Inc. reports revenue growth (2.6% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ELV or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 5.9/10). ELV trades at 13.3× P/E versus JNJ at 18.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ELV vs JNJ?
There are 21 analysts covering ELV with a consensus price target of $404.05, and 24 analysts covering JNJ with a consensus target of $252.96. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ELV or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 6.2/10). Net profit margin: ELV at 2.6%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ELV or JNJ?
Elevance Health, Inc. (ELV) scores higher on Financial Health (6.5/10 vs 6.5/10). Market beta: ELV at 0.67, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ELV and JNJ?
Elevance Health, Inc. (ELV) has a market capitalisation of $84.8B, while Johnson & Johnson (JNJ) has a market cap of $556.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ELV or JNJ pay dividends?
ELV pays a dividend yield of 1.76%, while JNJ pays a dividend yield of 2.32%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →